Dutch Bros is holding its annual Drink One for Dane Day of Giving fundraiser this Friday, May 15, with the Dutch Bros Foundation and franchisees donating $1 from every drink sold to support the fight against amyotrophic lateral sclerosis (ALS). The event raises funds and awareness of…
News
COYA 302, Coya Therapeutics’ investigational therapy for amyotrophic lateral sclerosis (ALS) — shown in an early clinical trial to slow disease progression in a small number of patients — has been awarded fast track status by the U.S. Food and Drug Administration (FDA). That designation is intended to…
The ALS Association has awarded $3 million to help expand access to specialized amyotrophic lateral sclerosis (ALS) care in underserved and geographically isolated communities across the U.S. The funding comes from the organization’s Hoffman ALS Clinic Development and Capacity Awards programs, established through a historic $58 million…
A cellular recycling system that degrades damaged or unwanted proteins is impaired in motor neurons from people with amyotrophic lateral sclerosis (ALS), suggesting it could be a target for future therapies aimed at slowing disease progression, according to a new study. The research also showed that motor neurons in…
EverythingALS has launched a new online tool called SAVA AI that uses artificial intelligence to instantly match people with amyotrophic lateral sclerosis (ALS) to clinical trials. The platform is available for free through the EverythingALS website or as a mobile app, providing patients with a secure way…
The U.S. Food and Drug Administration (FDA) has granted fast-track designation to tazbentetol, an experimental oral therapy being developed by Spinogenix for amyotrophic lateral sclerosis (ALS). Fast-track status is intended to speed the development and review of treatments for serious conditions with unmet medical needs. It will allow Spinogenix…
Acurastem has received $7.5 million in funding from the California Institute for Regenerative Medicine (CIRM) to advance AS-241, its lead clinical candidate for amyotrophic lateral sclerosis (ALS) and related diseases, toward clinical trials. The grant was supported by cell-based studies showing that AS-241 can restore certain ALS-related defects…
Following a recent meeting with the U.S. Food and Drug Administration (FDA), Clene is planning to submit an application asking the agency to approve its experimental therapy CNM-Au8 as a treatment for amyotrophic lateral sclerosis (ALS). The company specifically plans to file a new drug application (NDA)…
People with amyotrophic lateral sclerosis (ALS) who received a high dose of the experimental therapy dazucorilant had a significantly higher chance of survival than patients given a lower dose or no treatment. That’s according to new analyses of data from the DAZALS Phase 2 clinical trial (NCT05407324), which…
May is ALS Awareness Month, and in the U.S. and around the world, organizations are educating, sponsoring events, and encouraging the community to join them in taking action, providing financial support, and pushing for better access to care through advocacy for those living with amyotrophic lateral sclerosis. The…
Recent Posts
- ‘Emily in Paris’ actor Pierre Deny dies following severe case of ALS
- Why I continue to volunteer and stay involved in ALS causes
- We replace an old feeding tube part with a ‘lifetime supply’ of new parts
- Living near green space may reduce risk of developing ALS
- Traumatic head injury and ALS linked, but relationship still unclear: Review